Multiple Myeloma: Educating Patients on Oral Toxicity Management
Multiple myeloma specialists discuss patient education approaches regarding the management of oral toxicity stemming from talquetamab treatment and outline potential research approaches.
EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?
EP: 2.Overview of Relapsed/Refractory Multiple Myeloma
EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM
EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma
EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities
EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management
EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma
EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma
This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Catamero observes taste changes with talquetamab during step-up dosing, underscoring the need to set expectations about oral toxicities up front through detailed patient counseling. Good oral hygiene is stressed along with prophylactic interventions like saliva substitutes, dexamethasone rinses (used properly), nutritional consultations if there is a weight loss risk, and prompt treatment of suspected infections. Experimental icing and other anecdotal measures also continue to be tried. Rodriguez recommends combining any dexamethasone rinse with nystatin to prevent thrush. Repeated patient education with take-home references is vital. Overall, multifaceted patient support and customized adverse effect mitigation plans informed by risk stratifying data may best address these common challenges.
Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
